What are CDK 4/6 Inhibitors for Breast Cancer?

What is a CDK 4/6 inhibitor?Подробнее

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 InhibitionПодробнее

Current and future CDK4/6 inhibitors in high-risk early-stage HR+ breast cancerПодробнее

Episode 333: Pharmacology 101: CDK InhibitorsПодробнее

CDK 4/6 Inhibitors in Breast Cancer Advanced and Adjuvant SettingsПодробнее

Unmet Needs and Resistance Mechanisms in Patients with HR+, HER2- Metastatic Breast CancerПодробнее

Adjuvant CDK 4/6 Breast cancer #Abemaciclib-MonarchE or RIbociclib-NATALEE#DebateПодробнее

2024 Project Pitch Challenge: Presenter 9. Khai KoberПодробнее

CDK 4/6 Inhibitors in Breast Cancer Advanced and Adjuvant SettingsПодробнее

Are CDK 4/6 inhibitors being developed in TNBC?Подробнее

Impact of CDK4/6 inhibitors on HR-positive, HER2-negative advanced breast cancerПодробнее

Integrating Adjuvant CDK4/6 Therapy for HR+/Her2- EBC | Dr. Naresh Somani | Oncology 2024Подробнее

ASCO 2024: How to Best Use New Breast Cancer DataПодробнее

Prediction of CDK 4/6 Inhibitor Outcomes in Metastatic Breast Cancer Patients Using Exosomal miRNAsПодробнее

Continuation of Ribociclib After Progression on CDK4/6 inhibitorПодробнее

FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of RecurrenceПодробнее

ASCO 2024: What's New in Breast Cancer Research?Подробнее

What are the most common side effects of CDK 4/6 inhibitors (ribociclib, palbociclib, abemaciclib)?Подробнее

Prediction of CDK 4/6 Inhibitor Outcomes in Metastatic Breast Cancer Patients Using Exosomal miRNAsПодробнее

Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast CancerПодробнее